VIRIDIAN THERAPEUTICS INC (VRDN) Stock Analyst Ratings
USA - NASDAQ:VRDN - US92790C1045 - Common Stock
22.16 USD
+0.09 (+0.41%)
22.6993 USD
+0.54 (+2.43%)
ChartMill assigns a Buy % Consensus number of 85% to VRDN. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 37.88. This target is 70.92% above the current price.
VRDN was analyzed by 23 analysts. The buy percentage consensus is at 85. So analysts seem to be very confident about VRDN.
In the previous month the buy percentage consensus was at a similar level.
VRDN was analyzed by 23 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-10-21 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-08-07 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-08-07 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-08-07 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2025-08-07 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-08-06 | Needham | Maintains | Buy -> Buy |
| 2025-05-20 | Needham | Reiterate | Buy -> Buy |
| 2025-05-07 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2025-05-07 | Needham | Maintains | Buy -> Buy |
| 2025-05-07 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-05-07 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-04-23 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-07 | Needham | Reiterate | Buy -> Buy |
| 2024-12-19 | Wells Fargo | Downgrade | Overweight -> Equal-Weight |
| 2024-12-17 | RBC Capital | Maintains | Outperform -> Outperform |
| 2024-12-17 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-16 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-05 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2024-11-25 | TD Cowen | Initiate | Buy |
| 2024-11-25 | Needham | Reiterate | Buy -> Buy |
| 2024-11-14 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-11-13 | Needham | Reiterate | Buy -> Buy |
| 2024-10-28 | Needham | Reiterate | Buy -> Buy |
| 2024-09-26 | BTIG | Maintains | Buy -> Buy |
| 2024-09-19 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2024-09-13 | RBC Capital | Maintains | Outperform -> Outperform |
| 2024-09-12 | Goldman Sachs | Maintains | Buy -> Buy |
| 2024-09-11 | Needham | Maintains | Buy -> Buy |
| 2024-09-10 | BTIG | Maintains | Buy -> Buy |
| 2024-09-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
VIRIDIAN THERAPEUTICS INC / VRDN FAQ
What is the price target for VRDN stock?
23 analysts have analysed VRDN and the average price target is 37.88 USD. This implies a price increase of 70.92% is expected in the next year compared to the current price of 22.16.
Can you provide the consensus rating for VIRIDIAN THERAPEUTICS INC stock?
The consensus rating for VIRIDIAN THERAPEUTICS INC (VRDN) is 85.2174 / 100 . This indicates that analysts generally have a positive outlook on the stock.